Clarivate

JANUARY 8, 2024

The annual Clarivate Drugs to Watch report for 2024 features 13 new therapeutics with standout commercial and/or clinical potential. Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion for NSCLC and breast cancer combined.

Marketing 59

Marketing Patients Healthcare Healthcare 59

PM360

FEBRUARY 8, 2024

Silver Winner – Elevate Healthcare and Recordati Rare Diseases Inc. SYLVANT Can Open the Door SYLVANT is the only FDA-approved therapy for idiopathic multicentric Castleman disease (iMCD) that targets the underlying cytokine storm and can help deliver sustained symptomatic relief and durable tumor response.

Pharma 52

Pharma Medical sales Management Medical 52

Legacy MEDSearch

MARCH 7, 2024

Food and Drug Administration (FDA) announced the clearance of Dexcom’s device, marking it as the first continuous glucose monitor available over the counter. Dexcom disclosed its plans to make Stelo available for purchase online without the need for a prescription, starting in summer 2024. On March 5, the U.S. Are you hiring?

Food and Drug Administration 52

Food and Drug Administration FDA Food Management 52

Legacy MEDSearch

AUGUST 17, 2023

Welldoc ® , a digital health leader revolutionizing chronic care, today announced the receipt of its 10th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar ®. This enhanced functionality will be made available commercially in 2024.

FDA 52

FDA Food and Drug Administration Recruitment Management 52

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Sales 52

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. Additionally, its top-selling drug, Myalept or Myalepta, had third-quarter sales of $37.9m. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS represents five Amryt ordinary shares.

Pharma 88

Pharma Biopharma Management Medicine 88

Legacy MEDSearch

NOVEMBER 6, 2023

Histotripsy has been shown to be safe and effective in destroying targeted liver tumors, including unresectable liver tumors, recently gaining clearance from the FDA to market the Edison System for the non-invasive destruction of liver tumors, using a non-thermal, mechanical process of focused ultrasound.

Recruitment 52

Recruitment Physicians Medical Patients 52